BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCIES O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCIES O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
Enbrel O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

Enbrel O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

Reported O
infections B-OSE_Labeled_AE
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
latent I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Patients O
with O
tuberculosis B-OSE_Labeled_AE
have O
frequently O
presented O
with O
disseminated O
or O
extrapulmonary O
disease O
. O

Patients O
should O
be O
tested O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
before O
Enbrel O
use O
and O
during O
therapy O
. O

Treatment O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
should O
be O
initiated O
prior O
to O
Enbrel O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
histoplasmosis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
histoplasmosis B-OSE_Labeled_AE
or O
other O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

Empiric O
anti-fungal O
therapy O
should O
be O
considered O
in O
patients O
at O
risk O
for O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
who O
develop O
severe O
systemic O
illness O
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
, O
and O
other O
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
, O
including O
Legionella B-OSE_Labeled_AE
and O
Listeria O
. O

The O
risks O
and O
benefits O
of O
treatment O
with O
Enbrel O
should O
be O
carefully O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection I-OSE_Labeled_AE
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
Enbrel O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested O
negative O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
. O

MALIGNANCIES O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
including O
Enbrel O
. O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCIES O
See O
f O
ull O
p O
rescribing O
i O
nformation O
for O
complete O
b O
oxed O
w O
arning O
. O

SERIOUS O
INFECTIONS O
* O
Increased O
risk O
of O
serious O
infections O
leading O
to O
hospitalization O
or O
death O
, O
including O
tuberculosis O
( O
TB O
) O
, O
bacterial O
sepsis O
, O
invasive O
fungal O
infections O
( O
such O
as O
histoplasmosis O
) O
, O
and O
infections O
due O
to O
other O
opportunistic O
pathogens O
. O

( O
5.1 O
) O
* O
Enbrel O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection O
or O
sepsis O
during O
treatment O
. O

( O
5.1 O
) O
* O
Perform O
test O
for O
latent O
TB O
; O
if O
positive O
, O
start O
treatment O
for O
TB O
prior O
to O
starting O
Enbrel O
. O

( O
5.1 O
) O
* O
Monitor O
all O
patients O
for O
active O
TB O
during O
treatment O
, O
even O
if O
initial O
latent O
TB O
test O
is O
negative O
. O

( O
5.1 O
) O
MALIGNANCIES O
* O
Lymphoma O
and O
other O
malignancies O
, O
some O
fatal O
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
including O
Enbrel O
. O

( O
5.3 O
) O

